Venous (Vein) Thrombosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Venous (Vein) Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions.
Venous thromboembolism (VTE) is a condition characterized by the formation of blood clots in veins, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT typically manifests in deep veins, commonly in the lower leg, thigh, or pelvis, and can extend to the arms, particularly with intravenous central lines. Pulmonary embolism occurs when a detached clot travels to the lungs. With approximately 600,000 annual cases in the US, VTE is prevalent. Highest risk periods include major surgery, injury, or infections, where damaged veins and immobility contribute to clot formation. Symptoms include swelling, redness, and pain for DVT, while PE may present with sudden chest pain and shortness of breath.
The Venous (Vein) Thrombosis drugs in development market research report provide comprehensive information on the therapeutics under development for Venous (Vein) Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous (Vein) Thrombosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Venous (Vein) Thrombosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Venous (Vein) Thrombosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Venous (Vein) Thrombosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Venous (Vein) Thrombosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Anthos Therapeutics IncAPT Therapeutics Inc
Bayer AG
Beijing Kleb Pharmaceutical Development Co Ltd
Bio-Synectics Inc
CarboMimetics
Cereno Scientific AB
China Resources Emde Biological Pharmaceutical Co Ltd
Glycan Therapeutics Inc
Guangzhou Dazhou Biomedical Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Marizyme Inc
MDI Therapeutics Inc
Protheragen Inc
Shenyang Pharmaceutical University
Taho Pharmaceuticals Ltd
Tianjin Pharmaceuticals Group Co Ltd
Verseon Corp
Zerion Pharma AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Venous (Vein) Thrombosis reports